Rosiglitazone is effective and well-tolerated in a range of therapeutic regimens during daily practice in patients with type 2 diabetes

International Journal of Clinical Practice

Volumn 60, Issue 9, 2006, Pages 1040-1047

  Rosak, C ^a   Standl, E ^b   Reblin, T ^c   Stammer, H ^d   Seidel, Daniela K ^c  

^a KRANKENHAUS SACHSENHAUSEN   (Germany)

^b Klinikum Schwabing   (Germany)

^c GLAXOSMITHKLINE   (Germany)

^d Medical Statistics Consulting (MSC)   (Germany)

Author keywords

Combination therapy; Glycaemic control; Rosiglitazone; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; GLUCOSE; HEMOGLOBIN A1C; METFORMIN; ORAL ANTIDIABETIC AGENT; ROSIGLITAZONE; SULFONYLUREA;

ADULT; ANEMIA; ARTICLE; BODY WEIGHT; BODY WEIGHT DISORDER; CLINICAL PRACTICE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG TOLERABILITY; EDEMA; FEMALE; GERMANY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; STATISTICAL ANALYSIS; STROKE; SYSTOLIC BLOOD PRESSURE;

BLOOD GLUCOSE; BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; THIAZOLIDINEDIONES; WEIGHT LOSS;

EID: 33747177047     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2006.01092.x     Document Type: Article

References (36)

1. Fox CS, Coady S, Sorlie PD et al. Trends in cardiovascular complications of diabetes. JAMA 2004; 292: 2495-9.
2. Engelgau MM, Geiss LS, Saaddine JB et al. The evolving diabetes burden in the United States. Ann Intern Med 2004; 140: 945-50.
3. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. Br Med J 2000; 321: 405-12.
4. Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA 2004; 291: 335-42.
5. Haring HU, Joost HG, Matthaei S et al. Antihyperglykämische Therapie des Diabetes mellitus Typ 2. Diabetes Stoffwechsel 2003; 12 (Suppl. 2): 13-31.
6. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25 (Suppl. 1): S33-49.
7. International Diabetes Federation. Global Guideline for Type 2 Diabetes. http://www.idf.org/webdata/docs/IDF%20GGT2D.pdf2005.
8. Turner RC, Cull CA, Frighi V et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: Progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA 1999; 281: 2005-12.
9. Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996; 45: 1661-9.
10. Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes: scientific review. JAMA 2002; 287: 360-72.
11. Vongthavaravat V, Wajchenberg BL, Waitman JN et al. An international study of the effects of rosiglitazone plus sulphonylurea in patients with type 2 diabetes. Curr Med Res Opin 2002; 18: 456-61.
12. Fonseca V, Rosenstock J, Patwardhan R et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: A randomized controlled trial. JAMA 2000; 283: 1695-702.
13. Phillips LS, Grunberger G, Miller E et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Rosiglitazone Clinical Trials Study Group. Diabetes Care 2001; 24: 308-15.
14. Dirani R, Cobitz A, Wooddell M et al. Fewer self-reported gastrointestinal (GI) symptoms with addition of rosiglitazone (RSG) to sub-maximal dose of metformin (MET) compared to maximizing metformin dose in type 2 diabetes mellitus (T2DM) patients. Diabetes 2004; 53 (Suppl. 2): A122.
15. Rosenstock J, Goldstein BJ, Wooddell M et al. Greater benefits of rosiglitazone (RSG) added to submaximal dose of metformin (MET) compared to maximizing metformin dose in type 2 diabetes (T2DM) patients. Diabetes 2004; 53 (Suppl. 2): A144.
16. Rosenstock J, Goldstein B, Vinik AI et al. Effect of early addition of rosiglitazone to sulfonylurea therapy in older type 2 diabetes patients (>60 years): The Rosiglitazone Early vs. SULfonylurea Titration (RESULT) study. Diabetes Obes Metab 2006; 8: 49-57.
17. Sarafidis PA, Lasaridis AN, Nilsson PM et al. Ambulatory blood pressure reduction after rosiglitazone treatment in patients with type 2 diabetes and hypertension correlates with insulin sensitivity increase. J Hypertens 2004; 22: 1769-77.
18. Haffner S, Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-84.
19. Freed MI, Ratner R, Marcovina SM et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 947-52.
20. Yosefy C, Magen E, Kiselevich A et al. Rosiglitazone improves, while glibenclamide worsens blood pressure control in treated hypertensive diabetic and dyslipidemic subjects via modulation of insulin resistance and sympathetic activity. J Cardiovasc Pharmacol 2004; 44: 215-22.
21. GlaxoSmithKline. AVANDIA Summary of Product Characteristics. Available from http://www.emea.eu.int/humandocs/Humans/EPAR/Avandia/Avandia.htm (accessed 19 May 2006), 2005.
22. Scherbaum W, Landgraf R. Praxis-Leitlinien der Deutschen Diabetes-Gesellschaft. Diabetes Stoffwechsel 2002; 11 (Suppl. 2): 3-39.
23. Liebl A, Mata M, Eschwege E. Evaluation of risk factors for development of complications in Type II diabetes in Europe. Diabetologia 2002; 45: S23-8.
24. Dormandy JA, Charbonnel B, Eckland DJ et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366: 1279-89.
25. Oshinyemi K, Garcia S, Curtis P et al. Evaluation of the effects of rosiglitazone combination therapy on ambulatory blood pressure after 6 months; a 12 month substudy of the RECORD trial in people with Type 2 diabetes mellitus [abstract]. Diabetologia 2004; 47: A262.
26. Bennett SM, Agrawal A, Elasha H et al. Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance. Diabet Med 2004; 21: 415-22.
27. St John Sutton M, Rendell M, Dandona P et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes mellitus. Diabetes Care 2002; 25: 2058-64.
28. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53.
29. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-65.
30. Statistisches Bundesamt. Statistisches Jahrbuch 2001. Federal Statistical Office, Germany, 2005: 75-81.
31. Krebs J, Sowell M, Cobitz A. Ten years of rosiglitazone (RSG) clinical trial experience: A hepatic monitoring update. Diabetes 2005; 54: A21.
32. Dailey GE III, Noor MA, Park JS et al. Glycemic control with glyburide/ metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double-blind trial. Am J Med 2004; 116: 223-9.
33. Abel U, Koch A (eds). Nonrandomized Comparative Clinical Studies. Düsseldorf: Symposion Publishing, 1998.
34. Pfutzner A, Schondorf T, Seidel D et al. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Metabolism 2006; 55: 20-5.
35. Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
36. Viberti G, Kahn SE, Greene DA et al. A Diabetes Outcome Progression Trial (ADOPT): An international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25: 1737-43.